0001384101-21-000155.txt : 20210909
0001384101-21-000155.hdr.sgml : 20210909
20210909170735
ACCESSION NUMBER: 0001384101-21-000155
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210907
FILED AS OF DATE: 20210909
DATE AS OF CHANGE: 20210909
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kennedy Giulia C
CENTRAL INDEX KEY: 0001769333
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36156
FILM NUMBER: 211245104
MAIL ADDRESS:
STREET 1: 338 MAIN STREET #26E
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94105
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VERACYTE, INC.
CENTRAL INDEX KEY: 0001384101
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071]
IRS NUMBER: 205455398
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 6000 SHORELINE COURT, SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: (650) 243-6300
MAIL ADDRESS:
STREET 1: 6000 SHORELINE COURT, SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER COMPANY:
FORMER CONFORMED NAME: CALDEROME INC
DATE OF NAME CHANGE: 20061219
4
1
wf-form4_163122163694896.xml
FORM 4
X0306
4
2021-09-07
0
0001384101
VERACYTE, INC.
VCYT
0001769333
Kennedy Giulia C
6000 SHORELINE COURT
SUITE 300
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
Chief Scientific & Med Officer
Common Stock
2021-09-07
4
M
0
4406
5.98
A
55381
D
Common Stock
2021-09-07
4
M
0
3750
20.21
A
59131
D
Common Stock
2021-09-07
4
M
0
4375
24.69
A
63506
D
Common Stock
2021-09-07
4
S
0
12034
50.519
D
51472
D
Common Stock
2021-09-07
4
S
0
497
51.233
D
50975
D
Common Stock
2021-09-08
4
S
0
926
50.53
D
50049
D
Stock Option (right to buy)
5.98
2021-09-07
4
M
0
4406
0
D
2028-03-01
Common Stock
4406.0
8813
D
Stock Option (right to buy)
20.21
2021-09-07
4
M
0
3750
0
D
2029-02-27
Common Stock
3750.0
22500
D
Stock Option (right to buy)
24.69
2021-09-07
4
M
0
4375
0
D
2030-03-27
Common Stock
4375.0
43750
D
The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021.
Represents weighted average sales price. Sale prices for the transactions range from $50.06 to $51.06. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
Represents weighted average sales price. Sale prices for the transactions range from $51.07 to $51.33. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
The option becomes exercisable as to 25% of the shares on March 2, 2019, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.
The option becomes exercisable as to 25% of the shares on February 28, 2020, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.
The option becomes exercisable as to 25% of the shares on February 28, 2021, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.
/s/ Jane Alley as attorney-in-fact
2021-09-09